Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP615661.RAHuXdS95xDI_NgI85fVEK6LeiZyG8Oj78I4tQk1krwvo130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP615661.RAHuXdS95xDI_NgI85fVEK6LeiZyG8Oj78I4tQk1krwvo130_assertion type Assertion NP615661.RAHuXdS95xDI_NgI85fVEK6LeiZyG8Oj78I4tQk1krwvo130_head.
- NP615661.RAHuXdS95xDI_NgI85fVEK6LeiZyG8Oj78I4tQk1krwvo130_assertion description "[Despite more rapid onset and higher rate of CR than in other molecular subgroups, CRD was inferior in CCND1 without CD20 myeloma, resembling outcomes in MAF/MAFB and proliferation entities.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP615661.RAHuXdS95xDI_NgI85fVEK6LeiZyG8Oj78I4tQk1krwvo130_provenance.
- NP615661.RAHuXdS95xDI_NgI85fVEK6LeiZyG8Oj78I4tQk1krwvo130_assertion evidence source_evidence_literature NP615661.RAHuXdS95xDI_NgI85fVEK6LeiZyG8Oj78I4tQk1krwvo130_provenance.
- NP615661.RAHuXdS95xDI_NgI85fVEK6LeiZyG8Oj78I4tQk1krwvo130_assertion SIO_000772 20124509 NP615661.RAHuXdS95xDI_NgI85fVEK6LeiZyG8Oj78I4tQk1krwvo130_provenance.
- NP615661.RAHuXdS95xDI_NgI85fVEK6LeiZyG8Oj78I4tQk1krwvo130_assertion wasDerivedFrom befree-20140225 NP615661.RAHuXdS95xDI_NgI85fVEK6LeiZyG8Oj78I4tQk1krwvo130_provenance.
- NP615661.RAHuXdS95xDI_NgI85fVEK6LeiZyG8Oj78I4tQk1krwvo130_assertion wasGeneratedBy ECO_0000203 NP615661.RAHuXdS95xDI_NgI85fVEK6LeiZyG8Oj78I4tQk1krwvo130_provenance.